Bionoetikos

Bionoetikos is a biotechnology company founded to commercialize research regarding the Integrated Stress Response (ISR) pathway. The company's core technology centers on ISRIB, a potent small molecule inhibitor of the ISR that functions by activating the eIF2B complex. This mechanism aims to restore protein synthesis in stressed cells, offering a potential therapeutic approach for neurodegenerative conditions such as ALS and Vanishing White Matter Disease. Bionoetikos successfully licensed its technology to Calico Life Sciences, which is now advancing the lead candidate in clinical trials in partnership with AbbVie. The lead molecule, ABBV-CLS-7262, is currently being evaluated for its ability to improve cognitive and motor functions in patients with protein-folding disorders. While the company itself is no longer an active independent entity, its foundational work remains a cornerstone of current ISR-targeted drug development.